Acute leukemia;
FLT3/ITD;
FAB subtypes;
INTERNAL TANDEM DUPLICATION;
ACUTE MYELOID-LEUKEMIA;
MYELOGENOUS LEUKEMIA;
GENE;
ASSOCIATION;
ACTIVATION;
IMPACT;
D O I:
10.7314/APJCP.2012.13.9.4581
中图分类号:
R73 [肿瘤学];
学科分类号:
100214 ;
摘要:
Fms-like tyrosine kinase 3 (FLT3) performs a vital role in the pathogenesis of hematopoietic malignancies. Therefore in recent times, the focus of several studies was on use of FLT3 as a prognostic marker. The present study investigated the molecular characterization and incidence of FLT3 mutations in acute leukemia patients in Pakistan. A total of 55 patients were studied, of which 25 were suffering from acute lymphoblastic leukemia (ALL) and 30 were suffering from acute myeloid leukemia (AML). The polymerase chain reaction demonstrated FLT3/ITD mutations in 1 (4%) of 25 ALL patients, a male with the L2 subtype. In AML cases the rate was 4 (13.3%) of 30, three males and one female. The AML-M4 subtype was found in three and the AML M2 subtype in the other. In the AML cases, a statistically significant (p=0.009) relationship was found between WBC (109/L) and FLT3/ITD positivity. However, no significant relationship was found with other clinical parameters (p>0.05). In acute myeloid leukemia (AML) FLT3/ITD+ mutation was more prevalent in elderly patients 31-40 age groups, 21-30 and 51-60 age groups respectively. In acute lymphoblastic leukemia (ALL) statistically no significant relationship was found between clinical features and FLT3/ITD positivity (p>0.05). However, in acute lymphoblastic leukemia (ALL) FLT3/ITD+ mutation was more commonly found in age groups of 21-30.
机构:
Univ Calif San Francisco, Dept Med, Div Hematol Oncol, San Francisco, CA 94143 USAUniv Calif San Francisco, Dept Med, Div Hematol Oncol, San Francisco, CA 94143 USA
机构:
Yale New Haven Med Ctr, Dept Pharm, New Haven, CT 06511 USA
Yale New Haven Med Ctr, New Haven, CT 06511 USAYale New Haven Med Ctr, Dept Pharm, New Haven, CT 06511 USA
Zhao, Jennifer C.
Agarwal, Sonal
论文数: 0引用数: 0
h-index: 0
机构:
Yale New Haven Med Ctr, Dept Pharm, New Haven, CT 06511 USAYale New Haven Med Ctr, Dept Pharm, New Haven, CT 06511 USA
Agarwal, Sonal
Ahmad, Hiba
论文数: 0引用数: 0
h-index: 0
机构:
Yale New Haven Med Ctr, Dept Pharm, New Haven, CT 06511 USAYale New Haven Med Ctr, Dept Pharm, New Haven, CT 06511 USA
Ahmad, Hiba
Amin, Kejal
论文数: 0引用数: 0
h-index: 0
机构:
Yale New Haven Med Ctr, Dept Pharm, New Haven, CT 06511 USAYale New Haven Med Ctr, Dept Pharm, New Haven, CT 06511 USA
Amin, Kejal
Bewersdorf, Jan Philipp
论文数: 0引用数: 0
h-index: 0
机构:
Yale Univ, Sch Med, Dept Internal Med, New Haven, CT 06510 USA
Mem Sloan Kettering Canc Ctr, Leukemia Serv, Dept Med, 1275 York Ave, New York, NY 10021 USAYale New Haven Med Ctr, Dept Pharm, New Haven, CT 06511 USA
Bewersdorf, Jan Philipp
Zeidan, Amer M.
论文数: 0引用数: 0
h-index: 0
机构:
Yale Univ, Sch Med, Dept Internal Med, Sect Hematol, New York, NY USAYale New Haven Med Ctr, Dept Pharm, New Haven, CT 06511 USA
机构:
Harvard Med Sch, Dana Farber Canc Inst, Dept Med Oncol, 450 Brookline Ave,Dana 2058, Boston, MA 02215 USAHarvard Med Sch, Dana Farber Canc Inst, Dept Med Oncol, 450 Brookline Ave,Dana 2058, Boston, MA 02215 USA
Garcia, Jacqueline S.
Stone, Richard M.
论文数: 0引用数: 0
h-index: 0
机构:
Harvard Med Sch, Dana Farber Canc Inst, Dept Med Oncol, 450 Brookline Ave,Dana 2058, Boston, MA 02215 USAHarvard Med Sch, Dana Farber Canc Inst, Dept Med Oncol, 450 Brookline Ave,Dana 2058, Boston, MA 02215 USA
机构:
Astellas Pharma Inc, Res Program Management Off, Drug Discovery Res, 21 Miyukigaoka, Tsukuba Shi, Ibaraki 3058585, JapanAstellas Pharma Inc, Res Program Management Off, Drug Discovery Res, 21 Miyukigaoka, Tsukuba Shi, Ibaraki 3058585, Japan
Mori, Masamichi
Kaneko, Naoki
论文数: 0引用数: 0
h-index: 0
机构:
Astellas Pharma Inc, Res Program Management Off, Drug Discovery Res, 21 Miyukigaoka, Tsukuba Shi, Ibaraki 3058585, JapanAstellas Pharma Inc, Res Program Management Off, Drug Discovery Res, 21 Miyukigaoka, Tsukuba Shi, Ibaraki 3058585, Japan
Kaneko, Naoki
Ueno, Yoko
论文数: 0引用数: 0
h-index: 0
机构:
Astellas Pharma Inc, Res Program Management Off, Drug Discovery Res, 21 Miyukigaoka, Tsukuba Shi, Ibaraki 3058585, JapanAstellas Pharma Inc, Res Program Management Off, Drug Discovery Res, 21 Miyukigaoka, Tsukuba Shi, Ibaraki 3058585, Japan
Ueno, Yoko
Yamada, Masaki
论文数: 0引用数: 0
h-index: 0
机构:
Astellas Res Technol Co Ltd, Pharmacol Res Div, 21 Miyukigaoka, Tsukuba Shi, JapanAstellas Pharma Inc, Res Program Management Off, Drug Discovery Res, 21 Miyukigaoka, Tsukuba Shi, Ibaraki 3058585, Japan
Yamada, Masaki
Tanaka, Ruriko
论文数: 0引用数: 0
h-index: 0
机构:
Astellas Pharma Inc, Res Program Management Off, Drug Discovery Res, 21 Miyukigaoka, Tsukuba Shi, Ibaraki 3058585, JapanAstellas Pharma Inc, Res Program Management Off, Drug Discovery Res, 21 Miyukigaoka, Tsukuba Shi, Ibaraki 3058585, Japan
Tanaka, Ruriko
Saito, Rika
论文数: 0引用数: 0
h-index: 0
机构:
Astellas Pharma Inc, Res Program Management Off, Drug Discovery Res, 21 Miyukigaoka, Tsukuba Shi, Ibaraki 3058585, JapanAstellas Pharma Inc, Res Program Management Off, Drug Discovery Res, 21 Miyukigaoka, Tsukuba Shi, Ibaraki 3058585, Japan
Saito, Rika
Shimada, Itsuro
论文数: 0引用数: 0
h-index: 0
机构:
Astellas Pharma Inc, Res Program Management Off, Drug Discovery Res, 21 Miyukigaoka, Tsukuba Shi, Ibaraki 3058585, JapanAstellas Pharma Inc, Res Program Management Off, Drug Discovery Res, 21 Miyukigaoka, Tsukuba Shi, Ibaraki 3058585, Japan
Shimada, Itsuro
Mori, Kenichi
论文数: 0引用数: 0
h-index: 0
机构:
Astellas Pharma Inc, Res Program Management Off, Drug Discovery Res, 21 Miyukigaoka, Tsukuba Shi, Ibaraki 3058585, JapanAstellas Pharma Inc, Res Program Management Off, Drug Discovery Res, 21 Miyukigaoka, Tsukuba Shi, Ibaraki 3058585, Japan
Mori, Kenichi
Kuromitsu, Sadao
论文数: 0引用数: 0
h-index: 0
机构:
Astellas Pharma Inc, Res Program Management Off, Drug Discovery Res, 21 Miyukigaoka, Tsukuba Shi, Ibaraki 3058585, JapanAstellas Pharma Inc, Res Program Management Off, Drug Discovery Res, 21 Miyukigaoka, Tsukuba Shi, Ibaraki 3058585, Japan